Scholarlink

The WHO blamed COVID-19, a new coronavirus. HDCT of the lung can assess COVID-19 severity and progression. HRCT's rapid development may affect patients’ dosimetry. HRCT's dosimetric effects on COVID-19 patients are examined using ICRP 103 2007 guidelines for effective dosage, tissue dose, and cancer risk assessment. 100 HRCT-treated people of both genders were examined. The effective dosage was determined using the chest CT tissue conversion coefficient (k) and VirtualDoseTM CT software. The liver, breast, lungs, thyroid, colon, and stomach were examined. Breast, lung, stomach, and thyroid were utilized to predict cancer risk in 100,000 surgeries. ED DLP has 6.62 mSv, ED virtual 8.57. Male and female ED virtual mean scores differed greatly (p = 0.002). DLP and ED virtual are strongly associated (r = 0.741, p < 0.001). Females received higher equivalent dosage mean scores. Lung risk was higher in women. Males had the lowest thyroid cancer risk. The Pearson correlation showed no gender-specific age-related breast, lung, stomach, or thyroid cancer risk. Effective dosages, organ doses, and cancer risks are higher in women. ED dose-BMI nonlinearity. Lung and thyroid cancer chances were highest and lowest. Age does not affect gender cancer risk. Men had lower effective organ and cancer dosages than women. BMI and ED dose were nonlinear. DLP and ED virtual were quite positive. Lung and thyroid cancers are most and least dangerous. Age does not impact gender-specific cancer risk.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of High-Resolution CT-Based Dosimetry and Radiation Cancer Risk in COVID-19 Patients

  • 章节

  • 发表日期：

    2025年

查看全文
  • Lamis Z. M. Altalahmeh,
  • Sanaa A. El-Benhawy,
  • Enayat I. Fahmy,
  • Sanaa G. Alkhatib,
  • Muntaser S. Ahmad,
  • Kawther Faisal Amawi

摘要

The WHO blamed COVID-19, a new coronavirus. HDCT of the lung can assess COVID-19 severity and progression. HRCT's rapid development may affect patients’ dosimetry. HRCT's dosimetric effects on COVID-19 patients are examined using ICRP 103 2007 guidelines for effective dosage, tissue dose, and cancer risk assessment. 100 HRCT-treated people of both genders were examined. The effective dosage was determined using the chest CT tissue conversion coefficient (k) and VirtualDoseTM CT software. The liver, breast, lungs, thyroid, colon, and stomach were examined. Breast, lung, stomach, and thyroid were utilized to predict cancer risk in 100,000 surgeries. ED DLP has 6.62 mSv, ED virtual 8.57. Male and female ED virtual mean scores differed greatly (p = 0.002). DLP and ED virtual are strongly associated (r = 0.741, p < 0.001). Females received higher equivalent dosage mean scores. Lung risk was higher in women. Males had the lowest thyroid cancer risk. The Pearson correlation showed no gender-specific age-related breast, lung, stomach, or thyroid cancer risk. Effective dosages, organ doses, and cancer risks are higher in women. ED dose-BMI nonlinearity. Lung and thyroid cancer chances were highest and lowest. Age does not affect gender cancer risk. Men had lower effective organ and cancer dosages than women. BMI and ED dose were nonlinear. DLP and ED virtual were quite positive. Lung and thyroid cancers are most and least dangerous. Age does not impact gender-specific cancer risk.